SpaceX IPO launches today. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRoadside Real Regulatory News (ROAD)

Share Price Information for Roadside Real (ROAD)

Share Price is delayed by 15 minutes
Get Live Data
59.25    0.00 (0.00%)
Bid:
58.50
Ask:
60.00
Spread: 1.50 (2.564%)
Market Cap: £105.62m
ROAD Live PriceLast checked at - London Stock Exchange

Intraday Roadside Real Share Chart

Update on Cambridge Sleep Sciences

18 Feb 2025 07:00

RNS Number : 4250X
Roadside Real Estate PLC
18 February 2025
 

Roadside Real Estate plc

 

("Roadside" or the "Company")

 

Update on Cambridge Sleep Sciences

Clinical trial results

Appointment of new chief executive officer

 

 

Roadside (AIM: ROAD) provides the following update on its 47.8% investment holding in Cambridge Sleep Sciences ("CSS").

 

New clinical trial results released

CSS is pleased to announce the results of a second clinical trial of its SleepEngineTM technology, demonstrating its effectiveness in helping to improve the quality of adult sleep. The trial, led by Dr. Nigel Guest, showed that all participants using SleepEngineTM technology reported an improvement in their sleep quality.

 

The trial consisted of 19 adult participants with self-reported insomnia lasting over six months, who used a SleepHub® device featuring the SleepEngineTM technology for a period of 12 weeks. Their sleep quality was measured using a sleep diary and the globally respected Pittsburgh Sleep Quality Index, ("PQSI") rating scale ranging from 0 - 21, where higher scores indicate poorer sleep quality and a change of three points is considered significant.

 

From a baseline score of 11.21, the PSQI decreased by a statistically and clinically significant level of 4.21 (p

 

The latest trial results support the first unpublished trial of SleepEngineTM from 2016, where 92% of participants experienced an improvement in their sleep quality and an average increase in time asleep of 155 minutes. The latest trial results also reflect the anecdotal feedback received from users of the SleepHub® device over the last four years.

 

Appointment of new chief executive officer of CSS

CSS has appointed Adam Rostom as its chief executive officer with a mandate to accelerate CSS's commercial growth, seizing global licensing opportunities and expanding its presence in the bedding and wellness markets. His leadership will also drive the development of next-generation sleep solutions, working with health tracking brands to integrate continuous biomarker tracking with real-time sleep interventions.

 

Mr. Rostom has helped scale the businesses of household names including Innocent Drinks, Dyson, OVO Energy, Babylon Health and Many Pets. As a PhD biochemist with a passion for business, he has helped build and transform a number of high-growth businesses, blending creativity with commercial impact.

 

Former chief executive officer of CSS, Julian Stone, has been appointed President of the company, focusing on developing existing and new business globally.

 

CSS expects to issue a trading update on or around 28 February, 2025.

 

Charles Dickson, Executive Chairman of Roadside, said:

"This statistically significant trial proves our belief in CSS's technology as it continues to successfully help users improve their quality to sleep. We're excited by the diverse range of licensing opportunities the business is developing to find innovative new applications for its technology. I believe Adam and Julian will form a formidable combination to deliver the next chapter of CSS's story."

 

- Ends -

 

For more information

 

Roadside Real Estate plc

Charles Dickson, Executive Chairman

c/o Montfort

 

Cavendish Capital Markets Limited (Nomad and Joint Corporate Broker)

Carl Holmes / Seamus Fricker (Corporate Finance)

Tim Redfern / Jamie Anderson (ECM)

 

 

+44 (0)20 7220 0500

Stifel Nicolaus Europe Limited (Financial Adviser and Joint Corporate Broker)

Mark Young

Jonathan Wilkes-Green

Catriona Neville

 

+44 (0)20 7710 7600 

Montfort

Olly Scott

Bella Leathley

 

+44 (0)78 1234 5205

+44 (0)74 7168 7266

 

 

About Roadside

Roadside is a real estate business focused on building and scaling a high-quality portfolio of modern roadside retail assets, including modern EV charging infrastructure.

 

About Cambridge Sleep Sciences Ltd

Cambridge Sleep Sciences Ltd, is a legacy Life Sciences investment in which Roadside Real Estate plc holds a 47.8% interest. CSS develops technology which improves natural sleep. Using the principles of neuroscience and cutting-edge technology to enhance brain activity during sleep, its innovative solutions aim to improve health, wellbeing and enhance quality of life.

 

Its SleepEngineTM technology has been developed and refined over fifteen years by a team of researchers, scientists, sound engineers and medical experts. This unique technology produces sounds which emulate the waves created by the brain during sleep cycles. The sleep sounds guide the user's brain through the sequence of healthy sleep cycles, helping them fall asleep and achieve the quality of sleep they need in a consistent and optimal way.

 

Find out more at: www.cambridgesleepsciences.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAVDLFFELLXBBX
12
Date   Source Headline
28th May 20267:00 amRNSUpdate on Acquisitions
21st May 20267:00 amRNSProceeds from First Tranche of Put Option
29th Apr 20267:00 amRNSUpdate on Acquisitions and Debt Facility
23rd Apr 20267:00 amRNSDirector Dealings
20th Apr 20267:09 amRNSDirector Dealings and Changes to Concert Party
16th Apr 20267:00 amRNSDirector Dealings and Changes to Concert Party
13th Apr 202610:24 amRNSREPLACE: Acquisition of Hoch Group Limited
13th Apr 20267:30 amRNSGrant of Share Options
13th Apr 20267:00 amRNS£28.6 million acquisition of Hoch Group Limited
31st Mar 20267:00 amRNSExercise of First Tranche of Put Option Agreement
27th Mar 20267:00 amRNSAppointment of Joint Corporate Broker
24th Mar 202611:40 amRNSResult of AGM and Directorate Changes
24th Mar 20267:00 amRNSAGM Statement
13th Mar 202612:16 pmRNSNotification of Major Holdings
13th Mar 202612:16 pmRNSNotification of Major Holdings
27th Feb 20262:00 pmRNSNotice of AGM
25th Feb 20265:37 pmRNSNotification of Major Holdings
25th Feb 20267:22 amRNSCompletion of Acquisition
25th Feb 20267:00 amRNSNotification of Major Holdings
17th Feb 20266:28 pmRNSResult of Placing and Subscription
17th Feb 20265:36 pmRNSProposed Placing, Subscription & Acquisition
17th Feb 20265:03 pmRNSNotice of AGM & Board Appointment
17th Feb 20264:57 pmRNSIssue of Equity
17th Feb 20264:51 pmRNSAnnual Financial Report
9th Feb 20267:00 amRNSAmendment to Put Option Agreement
27th Jan 20267:40 amRNSNotice of Results
24th Dec 20257:00 amRNSAcquisition
28th Nov 202510:20 amRNSNotification of Major Holdings
27th Nov 20254:22 pmRNSNotification of Major Holdings
19th Nov 20253:10 pmRNSNotification of Major Holdings
10th Nov 20255:00 pmRNSNotification of Major Holdings
14th Oct 20257:00 amRNSYear End Update and Notice of Results 2025
29th Sep 20252:48 pmRNSResult of General Meeting
12th Sep 20257:00 amRNSDisposal
9th Sep 20257:00 amRNSAppointment of COO and LTIP Implementation
4th Jul 20257:00 amRNSAcquisition
30th Jun 20257:00 amRNSInterim Results for the six months ended 31.03.25
26th Jun 20257:00 amRNSSigning of £48 million put option agreement
17th Jun 202511:46 amRNSResult of AGM
23rd May 20257:00 amRNSNotice of Annual General Meeting (“AGM”)
8th May 20257:00 amRNSAppointment of new Chair
27th Mar 20257:00 amRNSDirector/PDMR Shareholding
28th Feb 20257:00 amRNSUpdate on partial sale of CSS shareholding to CGV
18th Feb 20257:00 amRNS-RUpdate on Cambridge Sleep Sciences
24th Dec 20247:00 amRNSFinal results for the year ended 30 September 2024
13th Dec 20247:15 amRNSNotice of results
13th Dec 20247:00 amRNSJoint venture acquisition
28th Oct 20247:00 amRNSRoadside JV acquires 12 stores from Lidl
1st Oct 20247:00 amRNSPartial sale of CSS shareholding
1st Oct 20247:00 amRNSDisposal of Barkby Pub Co. Ltd
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.